Skip to main
CRDL

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics Inc has demonstrated a statistically significant improvement in left ventricular mass and a favorable safety profile in its CardiolRx program, enhancing confidence in both the treatment of myocarditis and the broader application for inflammatory heart diseases. The clean safety profile of CardiolRx, alongside encouraging results from the ongoing Phase III MAVERIC trial, supports the company's strategic development of CRD-38, which targets heart failure and expands the market potential for its therapies. Additionally, the promising outcomes noted in the ARCHER program underline the efficacy of Cardiol's anti-inflammatory approach, suggesting increased partnership opportunities and de-risking for its recurrent pericarditis program.

Bears say

Cardiol Therapeutics Inc's current market capitalization of approximately $98 million suggests that the market does not attribute significant value to the advancements seen in the ARCHER trial or the potential offered by the CRD-38 program, indicating a lack of investor confidence in the company's growth prospects. Furthermore, while the ARCHER trial yielded crucial insights for de-risking CardiolRx's application in recurrent pericarditis, the results highlighted a reduction in statistical power for key endpoints, which may be perceived as an indication of limited clinical efficacy. Finally, the discontinuation of AZD3427 exemplifies the challenges faced by therapies reliant on vascular unloading, contrasting unfavorably with CRD-38's proposed mechanism, which may not sufficiently mitigate concerns regarding its differentiation and overall viability in a competitive market.

Cardiol Therapeutics (CRDL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of Apr 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.